IASO BIOPRODUCTION

Biopharmaceuticals vectored in eukaryotic microalgae cells, for oral-mucosal-topical delivery. Bioproduction of recombinant immunotoxins (gen3 RITs), of thermostable antigenic vaccines, through our own multigenic, stable and highly productive microalgae cell lines. USP by heterotrophic fermentation (mature technology). DSP by controlled cellular deconstruction (our key competence, intellectual property). Galenic pharmacology: active delivery and controlled release by microalgae whole cells, purified organelles, fragments, or extracts. Industrial extrapolation: manufacturing in commercial quantities, at reduced costs (factor 10-100 vs CHO), while respecting the quality requirements of the pharmaceutical industry. Platform for the contracted production of biomedicines, eventually extended to other ‘hostile’ molecules, to glycoproteins, monoclonal antibodies.

Medicine

0.00 K€